reports
- ING Helpdesk
- ING Helpdesk
Benelux Morning Notes
Ageas: The Saga continues. ASM International: KKR reportedly interested in ASM PT. D'Ieteren: Belron €8.1bn debt financing at better rates than expected. Elia: Challenges ahead, CEO appointment necessary. Gimv: €150-250m bond issue by Gimv controlling anchor investor WorxInvest. PostNL: Preparation letter on future of Dutch mail market sent to Parliament. Vonovia: Good progress on disposals
- Baptiste Lebacq
- Baptiste Lebacq
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Stefano Toffano
- Wim Gille
PostNL : Small, positive developments
>Normalised EBIT above ccs and AAOBe - FY24 remains a year marked by negative mix effects impacting the company’s results. Q2 24 group revenue was in line with ccs and our slightly below our expectations, coming it at € 795m for the quarter. Normalised EBIT was € 18m (€ 17m for Q2 23), an improvement yoy and higher than ccs and AAOBe. Free cash flow generation was negative during the quarter at € -19m, an improvement vs Q2 23 (€ -31m). The quarter was marked by unfa...
Oxurion Share Consolidation
Oxurion Share Consolidation Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, authorized by the General Meeting of July 24, 2024, will proceed with a consolidation of all existing shares. This consolidation will be carried out at a ratio of one (1) new share for ten thousand (10,000) existing shares. This share consolidation is a strategic step to increase the nominal value of the shares, simplify the capital structure, and improve th...
Oxurion Announces Results on the Extraordinary General Meeting (EGM) o...
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraordinary General Meeting on July 24, 2024. The shareholders approved all items on the agenda of the Extraordinary General Meeting. All documents pertaining to the Extraordinary General Meeting held on July 24, 2024, can be consulted on Oxurion’s website . About Oxurion Oxur...
- ING Helpdesk
Information on the Total Number of Voting Rights (Denominator) followi...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, ...
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 17, 2024, from Atlas Special Opportunities, LLC indicating that as of July 17, 2024, it held 941,611,204 shares of the then o...
- ING Helpdesk
Benelux Morning Notes
ASML: 2Q24 results; strong order intake. Barco: 1H24 results; guidance lowered. Basic-Fit: Preview 2Q24/1H24 results due 26 July. NSI: Some further limited write offs, guidance improved due to share buy back. PostNL: Dutch press interview with UPS CEO NL - expansion targeted at parcels NL
Oxurion provides clarification on the agenda of the extraordinary gene...
Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Leuven, BELGIUM – July 11, 2024 – 6:00pm CET – Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, announced today it has provided clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 (the EGM) as set out in the convening notice published on 5 July 2024 ...
Oxurion signs a Letter of Intent and enters into exclusive negotiation...
Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production LEUVEN, BELGIUM - July 8, 2024 – 6:30 pm, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces that it has signed a Letter of Intent (LOI) to enter into exclusive negotiations with a view to, subject to certain conditions, acquiring an 80% majority stake in a CRO (Contr...
- ING Helpdesk
Oxurion announces the results of the Extraordinary General Meeting (EG...
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024 Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024. Leuven, BELGIUM - 4 July 2024 – 6:00 PM CET, (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, informs its shareholders and the market that, at today's Extraordinary General Meeting, the attendance quorum required to deliberate and vote on the items on the agenda has not been reached, and that consequently,...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Michiel Declercq
- Thibault Leneeuw
- Thomas Vranken
- Wim Lewi
- Marc Zwartsenburg
- CEFA
PostNL/Investment case with multiple angles/BUY (previously Hold)
We upgrade our recommendation on PostNL from Hold to BUY and raise our target price from €1.30 to €1.65. As well as an accelerated March/April parcel volumes trend, we see: (a) cautious earnings forecasts with room for upside; (b) a potential positive trigger from a reduction in the number of delivery days which could lead to a significant structural saving for MailNL; (c) option value from speculation on a future merger triggered by developments at IDS where its large shareholder VESA has made ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.